# Joel Morse

> Joel Morse is the co-founder and CEO of Curavit Clinical Research, a virtual contract research organization (VCRO) that designs and runs decentralized clinical trials for digital therapeutics, devices and drugs. A mechanical engineer turned serial healthcare operator, he previously co-founded C3i Solutions in 1993 and built it into a global leader in tech-enabled clinical trial services before selling to Telerx in 2014. At Curavit he is betting that trials can be run where patients actually live, stitching together wearables, web recruitment and real-world evidence to reach people traditional sites never see.

- **Role:** CEO & Co-Founder at Curavit Clinical Research
- **Organizations:** Curavit Clinical Research, C3i Solutions, Telerx, American Express, American University in Bulgaria
- **Nationality:** American
- **Education:** BS, Mechanical Engineering (magna cum laude), Tufts University, MBA, International Business & Finance (high honors), Columbia University
- **Known for:** Co-founded and scaled C3i Solutions over ~20 years into a global tech-enabled clinical trial services leader before its acquisition by Telerx in 2014, Co-founded Curavit Clinical Research, a virtual CRO pioneering decentralized clinical trials, Led Curavit's completion of a fully virtual clinical trial for a digital therapeutic targeting PTSD symptoms

## Career timeline

- **pre-1993** — Senior manager at American Express
- **1993** — Co-founded C3i (later C3i Solutions) with Dave Hanaman and Diana Kyser
- **1993-2014** — Built C3i into a global leader in tech-enabled clinical trial services; clients included Medidata, Quintiles and Merck
- **2014** — C3i acquired by Telerx; Morse led Global Healthcare Operations and Global Process Excellence
- **2017** — Appointed President of Telerx and C3i Healthcare Connections
- **2020** — Co-founded Curavit Clinical Research, a virtual CRO for decentralized trials
- **2022** — Curavit raised a Series A (last raised November 2022)
- **2022-2023** — Curavit completed a fully virtual trial for Sana's investigational digital therapeutic for PTSD symptoms

## Achievements

- Co-founded and scaled C3i Solutions over ~20 years into a global tech-enabled clinical trial services leader before its acquisition by Telerx in 2014
- Co-founded Curavit Clinical Research, a virtual CRO pioneering decentralized clinical trials
- Led Curavit's completion of a fully virtual clinical trial for a digital therapeutic targeting PTSD symptoms
- Served on the board of trustees of the American University in Bulgaria, chairing the finance committee in 2014
- Published author/contributor on clinical trials topics (MedCity News, Applied Clinical Trials)

## Latest updates

- **2022-11** — Curavit's most recent funding round (Series A) closed.
- **2023-04** — Authored/contributed thought-leadership on the path of digital therapeutics from development to approval to access.

## Links

- Website: https://curavit.io
- LinkedIn: http://www.linkedin.com/in/morsejoel
- Twitter/X: https://twitter.com/curavitclinical

---

Profile page: https://yespress.io/joel-morse
Published by YesPress — https://yespress.io
Last updated: 2026-06-04